Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Fax: 781 642 0399

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Lionhart May. 13 at 11:12 AM

$KALA still the plan

0 · Reply

Fakhrul123 May. 13 at 6:46 AM

$KALA scam!!

0 · Reply

DH_trader May. 12 at 10:59 PM

$KALA shes so bullish, like INHD. Put all your money here, if you dont have a garbage bin

0 · Reply

We_the_People_Fight May. 12 at 9:04 PM

$KALA checking in... This is absolutely fuckery. Sorry guys

0 · Reply

Kennyk93 May. 12 at 8:28 PM

$KALA good day. Let's aim for another 20% drop tomorrow.

0 · Reply

oddlottrader May. 12 at 7:39 PM

$KALA dont save her, she dont wanna be saved - project pat

0 · Reply

LongLife1 May. 12 at 6:37 PM

$KALA how much cash have they raised and it’s not even holding 50m market cap

1 · Reply

Lionhart May. 12 at 5:23 PM

$KALA 2.50 is the target

1 · Reply

cmaryrealtor May. 12 at 5:16 PM

$KALA holy crap! Is anyone else holding this crap? I sure hate if someone is holding a lot of shares! ❤️

0 · Reply

Bigdubs May. 12 at 5:16 PM

$KALA wanna see my PT of under two. It’s sad to see investors lose but this was all spelled out in the horrible Cap Table after the failed pump. If you lost money here make it a learning lesson to understand the Cap Table. Real question after the shakeout here is WTF are they gonna do with 350m offering. Something that big needs another pivot or great news.

1 · Reply

Kala Bio falls -21.7%

2026-05-07T22:27:13.000Z - 5 days ago

Kala Bio files $350M mixed securities shelf

2026-05-07T18:28:35.000Z - 5 days ago

Kala Bio announces reverse stock split

May 7, 2026, 9:00 AM EDT - 5 days ago

KALA BIO Announces Reverse Stock Split

2026-04-21T12:34:59.000Z - 21 days ago

Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine

Apr 21, 2026, 7:00 AM EDT - 21 days ago

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 1, 2026, 6:45 AM EDT - 6 weeks ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Mar 30, 2026, 8:45 AM EDT - 6 weeks ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

2026-03-18T13:05:59.000Z - 7 weeks ago

Red Light Holland engages Kala Bio with its Researgency.ai platform

Mar 18, 2026, 9:00 AM EDT - 7 weeks ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 7 weeks ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 2 months ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

2026-03-11T12:00:18.000Z - 2 months ago

KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’

PLTR

2026-03-11T10:40:33.000Z - 2 months ago

Kala Bio poised to ship first commercial AI product in about 14 days

Mar 11, 2026, 6:30 AM EDT - 2 months ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

2026-03-04T11:45:29.000Z - 2 months ago

Kala Bio announces initiative to build AI infrastructure platform

Mar 4, 2026, 6:30 AM EST - 2 months ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

2026-02-10T11:15:48.000Z - 3 months ago

Kala Bio files to sell 241.44M shares of common stock for holders

Jan 30, 2026, 11:00 AM EST - 3 months ago

KALA BIO Transcript: AGM 2026

Jan 5, 2026, 4:10 PM EST - 4 months ago

KALA BIO Settles Approximately $10.6 million of Debt

2025-12-04T15:55:28.000Z - 5 months ago

Kala Bio announces $10M registered direct offering priced at-the-market

Dec 4, 2025, 10:45 AM EST - 5 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-12-01T12:11:04.000Z - 5 months ago

Kala Bio enters securities purchase agreement with David Lazar, names him CEO

2025-09-30T13:35:26.000Z - 8 months ago

Kala Bio downgraded to Neutral from Outperform at Mizuho

2025-09-29T17:25:13.000Z - 8 months ago

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

2025-09-29T17:25:08.000Z - 8 months ago

H.C. Wainwright downgrades Kala Bio to Neutral after CHASE trial miss

2025-09-29T15:20:15.000Z - 8 months ago

Kala Bio shared no details on study miss, says Mizuho

2025-09-29T15:15:13.000Z - 8 months ago

Kala Pharmaceuticals downgraded to Market Perform at LifeSci Capital

2025-09-29T13:40:36.000Z - 8 months ago

Kala Pharmaceuticals trading resumes

Sep 10, 2025, 2:00 PM EDT - 8 months ago

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 1:00 PM EDT - 9 months ago

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 8:00 AM EDT - 9 months ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 8:00 AM EDT - 9 months ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 16, 2025, 4:00 PM EDT - 10 months ago

KALA BIO Transcript: Status Update

Jul 9, 2025, 8:00 AM EDT - 10 months ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jun 5, 2025, 1:25 PM EDT - 1 year ago

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at Jefferies Global Healthcare Conference

Mar 5, 2025, 11:50 AM EST - 1 year ago

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Dec 4, 2024, 11:30 AM EST - 1 year ago

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Aug 15, 2024, 7:00 AM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 4, 2024, 12:50 PM EST - 2 years ago

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 13, 2024, 12:00 PM EST - 2 years ago

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Sep 5, 2023, 8:00 AM EDT - 2 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 2, 2023, 4:01 PM EDT - 3 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 3 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 6, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 19, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 9:33 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q1 2022

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Lionhart May. 13 at 11:12 AM

$KALA still the plan

0 · Reply

Fakhrul123 May. 13 at 6:46 AM

$KALA scam!!

0 · Reply

DH_trader May. 12 at 10:59 PM

$KALA shes so bullish, like INHD. Put all your money here, if you dont have a garbage bin

0 · Reply

We_the_People_Fight May. 12 at 9:04 PM

$KALA checking in... This is absolutely fuckery. Sorry guys

0 · Reply

Kennyk93 May. 12 at 8:28 PM

$KALA good day. Let's aim for another 20% drop tomorrow.

0 · Reply

oddlottrader May. 12 at 7:39 PM

$KALA dont save her, she dont wanna be saved - project pat

0 · Reply

LongLife1 May. 12 at 6:37 PM

$KALA how much cash have they raised and it’s not even holding 50m market cap

1 · Reply

Lionhart May. 12 at 5:23 PM

$KALA 2.50 is the target

1 · Reply

cmaryrealtor May. 12 at 5:16 PM

$KALA holy crap! Is anyone else holding this crap? I sure hate if someone is holding a lot of shares! ❤️

0 · Reply

Bigdubs May. 12 at 5:16 PM

1 · Reply

Nousernam3 May. 12 at 5:05 PM

$KALA tax loss write off. Not worth adding until they show a sign of run

0 · Reply

Nousernam3 May. 12 at 5:04 PM

$KALA LMFAOOOO BRO MAD. Me too man me too

0 · Reply

NatedoggAZ May. 12 at 5:03 PM

$KALA - you should be fucking embarrassed and kissing the fucking feet of your investors that you rammed up the ass....

0 · Reply

yahya_remontada May. 12 at 4:18 PM

$KALA this is a scam company their agent does not worth 1000 bucks

1 · Reply

SimplyFussFree May. 12 at 4:07 PM

$KALA Will be under a dollar before you know it…

1 · Reply

Nousernam3 May. 12 at 3:43 PM

$KALA enough shenanigans. Now run

0 · Reply

Ozunoy May. 12 at 3:40 PM

$KALA 🤢🤮

0 · Reply

Kennyk93 May. 12 at 3:34 PM

$KALA drop baby drop

0 · Reply

Lionhart May. 12 at 2:42 PM

$KALA still the plan

0 · Reply

TwongStocks May. 11 at 8:18 PM

Today's reverse split results. $AIXI 1 for 20 Previous close $0.6101, $12.202 split-adjusted Today's high $16.09 (premarket) Today's close $11.73 🔴Down 3.87% $ASBP 1 for 30 Previous close $0.1850, $5.55 split-adjusted Today's high $6.39 Today's close $5.52 🔴Down 0.54% $DKI 1 for 16 Previous close $0.3361, $5.3776 split-adjusted Today's high $5.75 Today's close $5.61 🟢Up 4.32% $KALA 1 for 50 Previous close $0.0793, $3.965 split-adjusted Today's high $3.98 (premarket) Today's close $3.91 🔴Down 1.39% $SMX 1 for 20 Previous close $1.11, $22.20 split-adjusted Today's high $34.00 (premarket) Today's close $14.49 🔴Down 34.73% As of this afternoon, NASDAQ does not have any reverse splits scheduled on Tuesday or Wednesday. Seems like this will be a fairly quiet week for RS's.

2 · Reply

yahya_remontada May. 11 at 5:04 PM

$KALA Lazar must be sued, maybe he's still dumping his shares. Anybody know at which price he got them?

3 · Reply

yahya_remontada May. 11 at 4:57 PM

$KALA pos

0 · Reply

Market Cap	72.69M
Revenue (ttm)	0.00
Net Income (ttm)	-26.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	168,700
Avg Vol	198,386
Day's Range	N/A - N/A
Shares Out	18.59M
Stochastic %K	9%
Beta	-2.23
Analysts	Strong Buy
Price Target	$1.50